Clinical Trials Sponsored by Immuron Ltd.

Total 16923 results

Immuron Ltd.

Terminated

Treatment for Clostridium-difficile Infection With IMM529

Clostridium Difficile Infection | Clostridium Difficile Infection Recurrence

Israel
Immuron Ltd.

Withdrawn

Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis
Immuron Ltd.

Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis (NASH)

United States, Australia, Israel
Incuron

Completed

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

Glioblastoma | Solid Tumors

United States
Incuron

Terminated

Study of IV CBL0137 in Previously Treated Hematological Subjects

Hematological Malignancies

United States
Immuron Ltd.
United States Department of Defense; Naval Medical Research Center

Active, not recruiting

Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model

Diarrhea | Infectious Diarrhea | Travelers Diarrhea

United States
Miriam Vos, MD
Immuron Ltd.; Advanced MR Analytics AB

Completed

Anti-LPS Antibody Treatment for Pediatric NAFLD

Nonalcoholic Fatty Liver Disease (NAFLD)

United States
Imunon

Not yet recruiting

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

SARS CoV 2 Infection

United States
Imunon

Completed

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA)

Hepatocellular Carcinoma

Korea, Republic of, China, Hong Kong, Singapore, Thailand, Malaysia, United States, Canada, Taiwan, Spain, Philippines, Germany, Italy, Vietnam
Imunon

Completed

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, Taiwan, Korea, Republic of, China, Italy, Hong Kong, Thailand, Canada, Malaysia, Japan, Philippines
Imunon

Completed

Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Imunon

Withdrawn

Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients (EURO-DIGNITY)

Breast Cancer

Israel, Czechia, Italy
Imunon

Completed

A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

Liver Neoplasms | Hepatocellular Carcinoma

United States
Imunon

Completed

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall (DIGNITY)

Breast Cancer

United States
Imunon

Active, not recruiting

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (OVATION 2)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Canada
Imunon

Terminated

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC) (ABLATE)

Colon Cancer Liver Metastasis

United States
Virginia Commonwealth University
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Immuron Ltd.

Completed

Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis (TREAT)

Hepatitis, Alcoholic

United States
IMMUNOe Research Centers

Completed

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

CVI - Common Variable Immunodeficiency

United States
IMMUNOe Research Centers

Unknown

Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Covid19 | Post-Viral Fatigue Syndrome | Post-Viral Disorder (Disorder)

United States
IMMUNOe Research Centers

Completed

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Primary Immunodeficiency
Bionor Immuno AS

Completed

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

HIV I Infection

Germany, United States, Spain, United Kingdom, Italy
Bionor Immuno AS

Completed

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

HIV-1 Infection

Norway
IMMUNOe Research Centers
Octapharma

Unknown

A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) (PANS)

Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections | Pediatric Acute-Onset Neuropsychiatric Syndrome

United States
Bionor Immuno AS

Completed

Re-boosting of HIV-1 Infected Subjects With Vacc-4x (Re-boost)

HIV-1 Infection

United States, Spain, Germany, Italy, United Kingdom
Imunon
Philips Healthcare

Withdrawn

MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases

Adenocarcinoma | Small Cell Lung Cancer | Breast Carcinoma | Non-small Cell Lung Cancer | Painful Bone Metastases
PrimeVax Immuno-Oncology Inc.

Not yet recruiting

Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma

Metastatic Melanoma
Fox Chase Cancer Center
Incuron

Suspended

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Locally Advanced or Metastatic Melanoma

United States
Roswell Park Cancer Institute
Incuron

Terminated

CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and... and other conditions

United States
Assistance Publique - Hôpitaux de Paris
Immunov

Terminated

Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics (COVADIS)

Autoimmune Diseases | Inflammatory Disorder

France
Imunon

Unknown

Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer

Breast Cancer

United States, United Kingdom
Bionor Immuno AS
Celgene Corporation

Completed

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (IMID)

HIV-1 Infection

Germany
Bionor Immuno AS
Celgene Corporation

Completed

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (REDUC)

HIV I Infection

Denmark
University of Miami
Immuno Laboratories

Completed

IgG-mediated Food Test for Weight Loss

Overweight and Obesity

United States
Imunon

Unknown

Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer

Breast Cancer

United States
Imunon
Break Through Cancer Foundation

Recruiting

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Imunon

Completed

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Tunisian Association for Immuno-oncology Research

Not yet recruiting

Biomarkers in Patients With Metastatic Breast Cancer (BIOPEACE)

Identify the Number of Eligible Patients for Immunotherapy According to the Epidemiological and Biological Profile in Tunisia
ImmunOs Therapeutics AG
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Solid Tumor, Adult

Australia
Assistance Publique - Hôpitaux de Paris
Fonds IMMUNOV

Completed

Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV) (AMBUCOV)

Covid19 | SARS-CoV-2

France
Immuno Cure 3 Limited
The University of Hong Kong

Active, not recruiting

Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)

COVID-19

Hong Kong
Shenzhen Immuno Cure Biomedical Company Limited
Shenzhen Third People's Hospital

Active, not recruiting

ICVAX as a HIV Therapeutic DNA Vaccine

Human Immunodeficiency Virus | Human Immunodeficiency Virus I Infection

China
Isaac Melamed
Bio Products Laboratory

Unknown

An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum

Autistic Disorder | Autism | Asperger's Disorder | Pervasive Developmental Disorder | PDD

United States
1st Allergy & Clinical Research Center

Completed

Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens

Atopic Dermatitis

United States
Children's Oncology Group
National Cancer Institute (NCI); Incuron LLC

Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Metastatic Malignant Neoplasm in the Central... and other conditions

United States
University of Oxford
Oxford University Hospitals NHS Trust; Imunon

Completed

Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours (TARDOX)

Liver Tumour

United Kingdom
The University of Hong Kong
Immuno Cure 3 Limited

Recruiting

A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19

Covid19

Hong Kong
Oslo University Hospital
Eurocine Vaccines AB; Bionor Immuno AS

Completed

Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant

HIV Infection

Norway
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

HIV Infections

United States

Clinical Trials Sponsored by Immuron Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations